Clinical trials · New Jersey
Glioma clinical trials in New Jersey
We’re tracking 17 recruiting glioma studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Hackensack, New JerseyAges 2–39 - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Morristown, New JerseyAges 2–21 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Hackensack, New JerseyAges 1–25 - NCT07110246RecruitingPhase 2
Dabrafenib and trametinib for BRAF-mutated low-grade gliomas
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
Hackensack, New JerseyAges 1–25 - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Hackensack, New JerseyAges 1–21 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Basking Ridge, New JerseyAges 16 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
New Brunswick, New JerseyAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Edison, New JerseyAges Up to 18 years - NCT05188508RecruitingPhase 2
Pembrolizumab, olaparib, and temozolomide for recurrent glioma
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
Basking Ridge, New JerseyAges 18 years+ - NCT05489783Recruiting
Study board for adults with NF1 and glioma
This study collects and reviews past and future health records for adults who have both neurofibromatosis type 1 (NF1) and a brain tumor called glioma. The goal is to better understand these conditions and how they progress, which can help guide future research and care.
Basking Ridge, New JerseyAges 18 years+ - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Neptune City, New JerseyAges Any age - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Hackensack, New JerseyAges 18 years+ - NCT06465199RecruitingPhase 1/Phase 2
Eflornithine and AMXT 1501 for Advanced Childhood Cancers
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Hackensack, New JerseyAges Up to 26 years - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Middletown, New JerseyAges 16 years+ - NCT07539441RecruitingPhase 1/Phase 2
Mirdametinib for brain and nervous system tumors
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Middletown, New JerseyAges 18 years+ - NCT07542158Enrolling by invitationPhase 2
Ultra-Low Radiation PET Imaging Study for Brain Scanning
This study tests a new way to take brain imaging scans (PET scans) using a very small amount of radioactive tracer. Researchers want to see if they can get clear pictures of your brain while reducing your radiation exposure compared to standard scans.
Englewood, New JerseyAges 18–120
Where these studies are running in New Jersey
Institutions with a site for the recruiting glioma studies listed above.
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Bergen · 5 studies
- Memorial Sloan Kettering Basking Ridge · 4 studies
- Rutgers Cancer Institute of New Jersey · 3 studies
- Hackensack University Medical Center · 2 studies
- Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center · 2 studies
- Morristown Medical Center · 2 studies
- Atlantic Health System
What taking part in a glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioma trials in other states
Common questions
- Are there glioma clinical trials in New Jersey?
- Yes. We're currently tracking 17 recruiting glioma studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioma study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioma studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.